<SEC-DOCUMENT>0001140361-21-034999.txt : 20211020
<SEC-HEADER>0001140361-21-034999.hdr.sgml : 20211020
<ACCEPTANCE-DATETIME>20211020163100
ACCESSION NUMBER:		0001140361-21-034999
CONFORMED SUBMISSION TYPE:	4
PUBLIC DOCUMENT COUNT:		1
CONFORMED PERIOD OF REPORT:	20211019
FILED AS OF DATE:		20211020
DATE AS OF CHANGE:		20211020

REPORTING-OWNER:	

	OWNER DATA:	
		COMPANY CONFORMED NAME:			HILL MATTHEW C
		CENTRAL INDEX KEY:			0001278675

	FILING VALUES:
		FORM TYPE:		4
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-37568
		FILM NUMBER:		211334518

	MAIL ADDRESS:	
		STREET 1:		C/O STRATA SKIN SCIENCES, INC.
		STREET 2:		5 WALNUT GROVE DRIVE, SUITE 140
		CITY:			HORSHAM
		STATE:			PA
		ZIP:			19044

	FORMER NAME:	
		FORMER CONFORMED NAME:	HILL MATHEW C
		DATE OF NAME CHANGE:	20040204

ISSUER:		

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			PDS Biotechnology Corp
		CENTRAL INDEX KEY:			0001472091
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				264231384
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	BUSINESS ADDRESS:	
		STREET 1:		25B VREELAND ROAD
		STREET 2:		SUITE 300
		CITY:			FLORHAM PARK
		STATE:			NJ
		ZIP:			07932
		BUSINESS PHONE:		800-208-3343

	MAIL ADDRESS:	
		STREET 1:		25B VREELAND ROAD
		STREET 2:		SUITE 300
		CITY:			FLORHAM PARK
		STATE:			NJ
		ZIP:			07932

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	Edge Therapeutics, Inc.
		DATE OF NAME CHANGE:	20090911
</SEC-HEADER>
<DOCUMENT>
<TYPE>4
<SEQUENCE>1
<FILENAME>form4.xml
<DESCRIPTION>FORM 4
<TEXT>
<XML>
<?xml version="1.0"?>
<ownershipDocument>

    <schemaVersion>X0306</schemaVersion>

    <documentType>4</documentType>

    <periodOfReport>2021-10-19</periodOfReport>

    <issuer>
        <issuerCik>0001472091</issuerCik>
        <issuerName>PDS Biotechnology Corp</issuerName>
        <issuerTradingSymbol>PDSB</issuerTradingSymbol>
    </issuer>

    <reportingOwner>
        <reportingOwnerId>
            <rptOwnerCik>0001278675</rptOwnerCik>
            <rptOwnerName>HILL MATTHEW C</rptOwnerName>
        </reportingOwnerId>
        <reportingOwnerAddress>
            <rptOwnerStreet1>C/O PDS BIOTECHNOLOGY CORPORATION</rptOwnerStreet1>
            <rptOwnerStreet2>25B VREELAND ROAD, SUITE 300</rptOwnerStreet2>
            <rptOwnerCity>FLORHAM PARK</rptOwnerCity>
            <rptOwnerState>NJ</rptOwnerState>
            <rptOwnerZipCode>07932</rptOwnerZipCode>
            <rptOwnerStateDescription></rptOwnerStateDescription>
        </reportingOwnerAddress>
        <reportingOwnerRelationship>
            <isOfficer>true</isOfficer>
            <officerTitle>Chief Financial Officer</officerTitle>
        </reportingOwnerRelationship>
    </reportingOwner>

    <derivativeTable>
        <derivativeTransaction>
            <securityTitle>
                <value>Stock Option (Right to Buy)</value>
            </securityTitle>
            <conversionOrExercisePrice>
                <value>12.03</value>
            </conversionOrExercisePrice>
            <transactionDate>
                <value>2021-10-19</value>
            </transactionDate>
            <transactionCoding>
                <transactionFormType>4</transactionFormType>
                <transactionCode>A</transactionCode>
                <equitySwapInvolved>0</equitySwapInvolved>
            </transactionCoding>
            <transactionAmounts>
                <transactionShares>
                    <value>202800</value>
                </transactionShares>
                <transactionPricePerShare>
                    <value>0</value>
                </transactionPricePerShare>
                <transactionAcquiredDisposedCode>
                    <value>A</value>
                </transactionAcquiredDisposedCode>
            </transactionAmounts>
            <exerciseDate>
                <footnoteId id="F1"/>
            </exerciseDate>
            <expirationDate>
                <value>2031-10-19</value>
            </expirationDate>
            <underlyingSecurity>
                <underlyingSecurityTitle>
                    <value>Common Stock</value>
                </underlyingSecurityTitle>
                <underlyingSecurityShares>
                    <value>202800</value>
                </underlyingSecurityShares>
            </underlyingSecurity>
            <postTransactionAmounts>
                <sharesOwnedFollowingTransaction>
                    <value>202800</value>
                </sharesOwnedFollowingTransaction>
            </postTransactionAmounts>
            <ownershipNature>
                <directOrIndirectOwnership>
                    <value>D</value>
                </directOrIndirectOwnership>
            </ownershipNature>
        </derivativeTransaction>
    </derivativeTable>

    <footnotes>
        <footnote id="F1">The option was granted by the Issuer as an inducement material to the Reporting Person entering into employment with the Issuer in accordance with Nasdaq Rule 5635(c)(4) and the Issuer's 2019 Inducement Plan, as amended.  The option will vest over four years, as follows: 25% of the shares underlying the option will vest and become exercisable on October 19, 2022, with the remaining 75% vesting in 36 equal monthly installments thereafter, subject to the Reporting Person's continued service to the Issuer through each vesting date.</footnote>
    </footnotes>

    <ownerSignature>
        <signatureName>/s/ Matthew C. Hill</signatureName>
        <signatureDate>2021-10-20</signatureDate>
    </ownerSignature>
</ownershipDocument>
</XML>
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
